drugset / Trial / NCT02860624

Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

NCT02860624

Phase 3 Completed 550 enrolled Livzon Pharmaceutical Group Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.

Timeline

Start
2011-12
Primary completion
2013-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 40 mg Oral
Subject Ilaprazole Small molecule 10 mg Oral